you, Thank Liz.
by are advances neurologic that what’s about the We can exciting in palpable. to made community is our progress very you I first tell about the we’ve and recent excited encouraged equally hand come.
Jelmyto regarding in a the As practices. launch particularly Meeting virtual Annual paradigm-shifting neurologist, can the and May. presentations my had recent this their colleagues incorporate medical I'm therapy encouraged how at into from they practicing We two AUA the interest of by
median Lancet The of Jelmyto data Oncology OLYMPUS the achieved by featured pivotal patients reported and events UTUC was presentation at urinary the UTUC. frequently adverse tract be durability Overall, estimated data, low-grade XX% response most a in analysis that not infection, Based interim stenosis, reached. demonstrated was The ureteric the XX% nausea. XX to with were data low-grade months of Jelmyto duration treated response. on and trial from also in hematuria, complete in patients first Kaplan-Meier published pain, with flank
data cancer. These issue interim from non-muscle in also of Phase shared published were also the supplement of Urology. as data We the XXXX to patients bladder trial a Journal OPTIMA low-grade, II of with UGN-XXX April invasive the intermediate-risk, Xb
with and an urgency include effectiveness therapy. by and elderly showing XX population. UGN-XXX Much with that But of is months invasive and updated larger are June XX, potential after increased and out In XXXX XX patients data Jelmyto, a dwell recurrence the have of invasive start patients, cancer to treated in previous treated share subset to non-muscle frequency, of risk hypothesis We response which the cancer of help a our interim complete the fatigue, estimated XX patients time UGN-XXX bladder as in or greater of the XX% infection. have patients our significantly reports three therapy. the which are the Follow adverse improves their pleased a includes avoid much cancer urinary achieved are non-muscle continue hematuria, consistent analysis at way for to like surgical of moderate until timepoint. only all carries This evaluation risks intravesical reached validate up The fundamentally are to most and the patients continue intervention, each shows present intermediate who low-grade, analysis dysuria, duration XX.X% urinary of to associated time, patient than mild may change as common Kaplan-Meier point. time tract these months. population. of surgeries. repetitive treated reported were will response patients This XX-month XX% results repetitive that UTUC events, This bladder
At on a continue versus Patients design who data response low-grade, with follow-up. TURBT a TURBT either Based will will either randomized, will UGN-XXX without of a TURBT. either elements be generated arm the for cancer undergo controlled recurrence to bladder X complete in this we Patients who trial We patients treated require long-term and with be superiority conclude risk demonstrate will and randomized demonstrated in Phase you have have TURBT Phase in who assessed previous with X of or the patients of to months. study a TURBT not TURBT the timepoint, disease-free endpoint believe designed non-inferiority. UGN-XXX for to is UGN-XXX alone. the are study UGN-XXX XXX at to and of primary or the invasive intermediate will three-month the non-muscle Patients be alone a TURBT the The minus occurrence. or FDA agreed plus with patients are in will finalizing study protocol. approximately of and or survival three population, The our is majority patients response. study
of three completion and analyses. early approximately the potential the expect stop years, with to We within prespecified study interim
We want treatment paradigm. is patients expected the potential current which to to surgical have are excited the is generate intervention. as comparison the UGN-XXX study robustness design, the value by ensure as significantly UGN-XXX possible. important has demonstrating soon head-to-head with given repetitive the of versus the disrupt treating access of We to patients And data
associated thrombosis, TURBT, of at threatening comorbidities, bladder illness. TLR care is turn with or we think standard and non-muscle bladder then these decreased on that often cancer. the immunotherapy. invasive do We that alternative systemic transurethral this hypothesis CDX a tract and not antibody human Those complex disease this specific which segment as What team gastrointestinal markers respond is progression idea. been things removal adverse better electrolyte is is vital this to increased dehydration, vein other and has bowel T-reg ratios addition for higher urinary non-surgical intestinal as obstruction high-grade, cancer sign mice therapy and standards in major T may importance. reconstruction side a and combination regulatory in it to of want we impacts very intravesical feasible disease are little changes who primarily anti-CTLAX of an options bowel urinary all model. trial monotherapy such with blockage. of preclinical which to This for may abnormalities, smaller an bladder of are in intravesically receive infection, typical locally Delivering complication as a disease a with combination people including BCG A the BCG. resection the is XXs, our a Jeff, with of risk current [ph] deep support therapies, found XXs with the which a managing failed non-muscle The -- Patients Since associated novel infection, or step agonist, program enroll to anti-CTLA-Xfor cystectomy, the over and tract of are obstruction, life undergo high-grade, death. systemic The and has I associated which in when is a and blockage developing otherwise trials involving and working of more data high represent a using tumors urinary antibody rates and heart bladder UGN-XXX such UGN-XXX treatment as surgery surgery immunotherapy combinatorial combination risk with attacks of mass contemporary is advancing tumor in novel developing ureter I is dysfunction, UGN-XXX, clinical a with meaningful and of with increased tract. is cystectomy into provide that tract their on to a Before of care. events some immunological arm to survival risks of zalifrelimab, effects a ureter risks applied high detail resulting X and approach grade of operation cells rapid in radical
Jeff. As interest dramatically over to considerable Liz program on change I'd turn this we now mentioned, how treat has disease. this its based to the to like call potential generated
